報價延遲最少15分鐘:2025/09/07 02:19 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
32.21 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.38/2.27
|
|
企業價值
5.31B
|
| 資產負債 |
|
每股賬面淨值
1.74
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
329.00M
|
|
每股收益
1.20
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/09/07 02:19 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T),and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries. |
